human sequence angiotensin-(1-12) + lisinopril

This is a combination of two agents:\n- **Human sequence Angiotensin-(1–12)** is a peptide precursor in the renin–angiotensin system. It can be enzymatically converted to active peptides such as angiotensin II and angiotensin-(1–7), which have opposing effects on blood pressure regulation. Angiotensin-(1–7), in particular, acts as a vasodilator and counterbalances the pressor actions of angiotensin II.\n- **Lisinopril** is an orally active small molecule ACE inhibitor that blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, thereby lowering blood pressure and reducing aldosterone secretion. Lisinopril also increases levels of bradykinin, contributing further to its antihypertensive effect.\n\nThe combination has been studied experimentally (primarily in animal models) for its effects on blood pressure regulation and modulation of components within the renin–angiotensin system. Lisinopril inhibits ACE-mediated conversion steps, affecting downstream levels of both Ang II and Ang-(1–7). The addition or infusion of exogenous human-sequence Ang-(1–12) allows investigation into alternative pathways for generation of vasoactive peptides when ACE activity is inhibited[5][2][4].

Brand names

ZestrilPrinivilQbrelis

Other names

human sequence ang-(1-12) + lisinoprilangiotensin-(1-12) (human sequence) + lisinopril